Multiple medication use in patients seen in the Veterans Affairs healthcare system: So what?

Journal of Psychiatric Practice

Volumn 11, Issue 1, 2005, Pages 46-50

  Preskorn, Sheldon H ^a,b  

^a UNIVERSITY OF KANSAS SCHOOL OF MEDICINE WICHITA   (United States)

^b University of Montreal   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ESCITALOPRAM; FLUOXETINE; MIRTAZAPINE; PAROXETINE; PSYCHOTROPIC AGENT;

DRUG MONITORING; DRUG USE; HEALTH CARE SYSTEM; HUMAN; MENTAL DISEASE; POLYPHARMACY; PRESCRIPTION; REVIEW; SOLDIER;

ADOLESCENT; ADULT; AGED; CYTOCHROME P-450 CYP2D6; FEMALE; HUMANS; INCIDENCE; MALE; MENTAL DISORDERS; MENTAL HEALTH SERVICES; MIDDLE AGED; POLYPHARMACY; UNITED STATES; UNITED STATES DEPARTMENT OF VETERANS AFFAIRS;

EID: 12844289008     PISSN: 15274160     EISSN: None     Source Type: Journal    
DOI: 10.1097/00131746-200501000-00006     Document Type: Review

References (28)

1. Preskorn SH, Silkey B, Shah R, et al. Complexity of medication use in the Veterans Affairs healthcare system: Part I. Outpatient use in relation to age and number of prescribers. J Psychiatr Pract 2005;11:5-15.
2. Silkey B, Preskorn SH, Golbeck A, et al. Complexity of medication use in the Veterans Affairs healthcare system: Part II. Antidepressant use among younger and older outpatients. J Pract Psychiatry 2005;11:16-26.
3. Preskorn SH. A message from Titanic. Journal of Practical Psychiatry and Behavioral Health 1998;4:236-42.
4. Preskorn SH. Classification of neuropsychiatric medications by principal mechanism of action: A meaningful way to anticipate pharmacodynamically mediated drug interactions. J Psychiatr Pract 2003;9:376-84.
5. Preskorn SH. Classification of neuropsychiatric medications by principal mechanism of action: A meaningful way to anticipate pharmacodynamically mediated drug interactions (Part II). J Psychiatr Pract 2004;10:177-81.
6. Preskorn SH. Imipramine, mirtazapine, and nefazodone: Multiple targets. J Psychiatr Pract 2000;6:97-102.
7. Preskorn SH. Reproducibility of the in vivo effect of the selective serotonin reuptake inhibitors on the in vivo function of cytochrome P450 2D6: An update (Part I). J Psychiatr Pract 2003;9:150-8.
8. Preskorn SH. Reproducibility of the in vivo effect of the selective serotonin reuptake inhibitors on the in vivo function of cytochrome P450 2D6: An update (Part II). J Psychiatr Pract 2003;9:228-36.
9. Levy RH, Thummel KE, Trager WF, et al. Metabolic drug interactions. Philadelphia: Lippincott, Williams & Wilkins, 2000.
10. Flockhart DA. Drug interactions website. http://medicine.iupui.edu/ flockhart (Accessed December 2004).
11. Heneryck A, Lefebvre RA, De Vriendt C, et al. Paroxetine affects metoprolol pharmacokinetics and pharmacodynamics in healthy volunteers. Clin Pharm Ther 2000;67:283-91.
12. Preskorn SH. Relating clinical trials to psychiatric practice: Part I: The case of a 13-year-old on aripiprazole and fluoxetine. J Psychiatr Pract 2003;9:307-12.
13. U.S. Department of Health and Human Services, Centers for Disease Control and Prevention, National Center for Health Statistics. Health, United States 2004. Hyattsville, MD, 2004 (Can be accessed at www.cdc.gov/nchs/hus.htm).
14. Preskorn SH. Do you feel lucky? Journal of Practical Psychiatry and Behavioral Health 1998;4:37-40.
15. Nichol MB, Stimmel GL, Lange SC. Factors predicting the use of multiple psychotropic medications. J Clin Psychiatry 1995;56:60-6.
16. Jaffe AB, Levine J. Antipsychotic medication coprescribing in a large state hospital system. Pharmacoepidemiol Drug Saf 2003;12:41-8.
17. Centorrino F, Eakin M, Bahk WM, et al. Inpatient antipsychotic drug use in 1998, 1993, and 1989. Am J Psychiatry. 2002;159:1932-5.
18. Frye MA, Ketter TA, Leverich GS, et al. The increasing use of polypharmacotherapy for refractory mood disorders: 22 years of study. J Clin Psychiatry 2000;61:9-15.
19. Preskorn SH. "I don't see 'em." Journal of Practical Psychiatry and Behavioral Health 1997;3:302-7.
20. Preskorn SH. The case studies section. Series of columns published in the Journal of Psychiatric Practice (www.preskorn .com/column1.html).
21. Preskorn SH. The slippery slide. Journal of Practical Psychiatry and Behavioral Health 1999;5:50-5.
22. Preskorn SH. Do you believe in magic? Journal of Practical Psychiatry and Behavioral Health 1997;3:99-100.
23. Preskorn SH. Use of antidepressants with other medications. In: Preskorn SH, editor. Outpatient Management of Depression. Caddo, OK: Professional Communications Inc.; 1999: 179-92.
24. Shad MU, Preskorn SH. Pharmacodynamic and pharmacokinetic factors in a case of neuroleptic malignant syndrome (letter). J Clin Psychopharmacol 1998;18:346-7.
25. Bertschy G, Baumann PA, Eap CB, et al. Probable metabolic interaction between methadone and fluvoxamine in addict patients. Ther Drug Monit 1994;16:42-5.
26. Preskorn S. Clinical pharmacology case conference: A suicide attempt? J Psychiatr Pract 2002;8:306-10.
27. Ray WA, Murray KT, Meredith S, et al. Oral erythromycin and the risk of sudden death from cardiac causes. N Engl J Med 2004;351:1089-96.
28. Preskorn SH. Relating clinical trials to psychiatric practice: Part II: The gap between the usual patient in registration trials and in practice. J Psychiatr Pract 2003;9:455-61.